Shares of Penumbra, Inc. (NYSE:PEN - Get Rating) have been assigned an average recommendation of "Moderate Buy" from the fourteen brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $234.18.
A number of research firms recently issued reports on PEN. Jefferies Financial Group began coverage on Penumbra in a report on Wednesday, October 12th. They issued a "buy" rating and a $230.00 price target for the company. Truist Financial lifted their price target on Penumbra from $228.00 to $255.00 and gave the company a "buy" rating in a report on Tuesday, December 20th. Canaccord Genuity Group dropped their price objective on Penumbra from $203.00 to $185.00 and set a "buy" rating for the company in a report on Friday, November 4th. BTIG Research boosted their price objective on Penumbra from $204.00 to $240.00 and gave the stock a "buy" rating in a report on Monday, December 5th. Finally, StockNews.com cut Penumbra from a "hold" rating to a "sell" rating in a report on Wednesday, November 23rd.
Penumbra Stock Up 0.3 %
Shares of NYSE:PEN opened at $222.46 on Tuesday. Penumbra has a 52 week low of $114.86 and a 52 week high of $290.36. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.92 and a current ratio of 5.23. The company's fifty day moving average is $200.44 and its 200-day moving average is $174.48. The company has a market capitalization of $8.45 billion, a PE ratio of -271.29 and a beta of 0.48.
Penumbra (NYSE:PEN - Get Rating) last released its quarterly earnings results on Thursday, November 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02. Penumbra had a positive return on equity of 0.45% and a negative net margin of 3.68%. The business had revenue of $213.68 million during the quarter, compared to analysts' expectations of $212.41 million. Equities research analysts predict that Penumbra will post 0.14 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Penumbra news, EVP Johanna Roberts sold 1,500 shares of the stock in a transaction on Thursday, December 1st. The stock was sold at an average price of $210.29, for a total transaction of $315,435.00. Following the transaction, the executive vice president now owns 55,310 shares in the company, valued at approximately $11,631,139.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 5.50% of the company's stock.
Institutional Trading of Penumbra
Large investors have recently modified their holdings of the stock. Hanseatic Management Services Inc. acquired a new stake in shares of Penumbra during the 3rd quarter worth $35,000. Wipfli Financial Advisors LLC acquired a new stake in shares of Penumbra during the 3rd quarter worth $40,000. Captrust Financial Advisors grew its holdings in shares of Penumbra by 44.1% during the 2nd quarter. Captrust Financial Advisors now owns 219 shares of the company's stock worth $27,000 after purchasing an additional 67 shares in the last quarter. WASHINGTON TRUST Co acquired a new stake in shares of Penumbra during the 2nd quarter worth $31,000. Finally, Covestor Ltd grew its holdings in shares of Penumbra by 190.8% during the 1st quarter. Covestor Ltd now owns 442 shares of the company's stock worth $98,000 after purchasing an additional 290 shares in the last quarter. 82.42% of the stock is owned by institutional investors and hedge funds.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to EMAIL.
Before you consider Penumbra, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.
While Penumbra currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here